a drug effective for a serious disorder is less and less effective as it is promoted for milder cases and for other conditions for which the drug was not approved. although effectiveness becomes more diluted, the risks of harmful side effects persist, and thus the benefit-harm ratio worsens as a drug is marketed more widely. the inverse benefit law highlights the need for comparative effectiveness research and other reforms to improve evidence-based prescribing.